Thermo Fisher Scientific Human Siglec-2 (CD22) (soluble) Recombinant Protein, PeproTech

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

View 1 publication 1 publication

Functional Assay (Functional)

Assay-dependent

-

Product Specifications

Species

Human

Published species

Human

Expression System

CHO cells

Amino acid sequence

SKWVFEHPET LYAWEGACVW IPCTYRALDG DLESFILFHN PEYNKNTSKF DGTRLYESTK DGKVPSEQKR VQFLGDKNKN CTLSIHPVHL NDSGQLGLRM ESKTEKWMER IHLNVSERPF PPHIQLPPEI QESQEVTLTC LLNFSCYGYP IQLQWLLEGV PMRQAAVTST SLTIKSVFTR SELKFSPQWS HHGKIVTCQL QDADGKFLSN DTVQLNVKHT PKLEIKVTPS DAIVREGDSV TMTCEVSSSN PEYTTVSWLK DGTSLKKQNT FTLNLREVTK DQSGKYCCQV SNDVGPGRSE EVFLQVQYAP EPSTVQILHS PAVEGSQVEF LCMSLANPLP TNYTWYHNGK EMQGRTEEKV HIPKILPWHA GTYSCVAENI LGTGQRGPGA ELDVQYPPKK VTTVIQNPMP IREGDTVTLS CNYNSSNPSV TRYEWKPHGA WEEPSLGVLK IQNVGWDNTT IACARCNSWC SWASPVALNV QYAPRDVRVR KIKPLSEIHS GNSVSLQCDF SSSHPKEVQF FWEKNGRLLG KESQLNFDSI SPEDAGSYSC WVNNSIGQTA SKAWTLEVLY APRRLRVSMS PGDQVMEGKS ATLTCESDAN PPVSHYTWFD WNNQSLPHHS QKLRLEPVKV QHSGAYWCQG TNSVGKGRSP LSTLTVYYSP ETIGRR

Molecular weight

75 kDa

Class

Recombinant

Type

Protein

Purity

≥ 98% by SDS-PAGE gel and HPLC analyses.

Endotoxin concentration

<1 EU/µg

Activity

Determined by its ability to inhibit the proliferation of Raji cells. The expected ED50 for this effect is 10-17 ug/ml.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Lyophilized

Purification

purified

Contains

no preservative

Storage conditions

-20°C

Shipping conditions

Ambient

Product Specific Information

Recombinant Human CD22 is a soluble 75.0 kDa protein which corresponds to the extracellular domain of CD22.

This product is shipped at ambient temperature. For storage, handling and reconstitution information, please see the lot-specific Certificate of Analysis

Target Information

CD22 (BL-CAM) is a type 1 integral membrane glycoprotein with molecular weight of 130 to 140 kDa. CD22 is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-), and may thus prove useful in phenotyping mature leukemias. CD22 is also strongly expressed in hairy cell leukemia. CD22 preferentially binds to alpha2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B cell antigen receptor signaling. CD22 plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. CD22 is also strongly expressed in hairy cell leukemia. CD22 is also positive in diffuse large B-cell lymphoma and nodular lymphocyte predominance Hodgkins lymphoma, but negative in classical Hodgkins lymphoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.